Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

This company has been moved to the archive! The financial data has not been updated since May 1, 2025.

Enterprise Value (EV) 

Microsoft Excel

Current Enterprise Value (EV)

CVS Health Corp., current enterprise value calculation

Microsoft Excel
Current share price (P) $69.45
No. shares of common stock outstanding 1,265,019,429
US$ in millions
Common equity (market value)1 87,856
Add: Preferred stock, par value $0.01; none issued or outstanding (per books)
Add: Noncontrolling interests (per books) 170
Total equity 88,026
Add: Short-term debt (per books) 2,119
Add: Current portion of long-term debt (per books) 3,624
Add: Long-term debt, excluding current portion (per books) 60,527
Total equity and debt 154,296
Less: Cash and cash equivalents 8,586
Less: Investments 2,407
Enterprise value (EV) 143,303

Based on: 10-K (reporting date: 2024-12-31).

1 Common equity (market value) = Share price × No. shares of common stock outstanding
= 69.45 × 1,265,019,429


Historical Enterprise Value (EV)

CVS Health Corp., EV calculation

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Share price1, 2 $63.22 $76.05 $88.96 $104.79 $70.53
No. shares of common stock outstanding1 1,260,795,063 1,258,449,553 1,284,111,667 1,312,510,426 1,311,354,926
US$ in millions
Common equity (market value)3 79,707 95,705 114,235 137,538 92,490
Add: Preferred stock, par value $0.01; none issued or outstanding (book value)
Add: Noncontrolling interests (book value) 170 175 300 306 312
Total equity 79,877 95,880 114,535 137,844 92,802
Add: Short-term debt (book value) 2,119 200
Add: Current portion of long-term debt (book value) 3,624 2,772 1,778 4,205 5,440
Add: Long-term debt, excluding current portion (book value) 60,527 58,638 50,476 51,971 59,207
Total equity and debt 146,147 157,490 166,789 194,020 157,449
Less: Cash and cash equivalents 8,586 8,196 12,945 9,408 7,854
Less: Investments 2,407 3,259 2,778 3,117 3,000
Enterprise value (EV) 135,154 146,035 151,066 181,495 146,595

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Data adjusted for splits and stock dividends.

2 Closing price as at the filing date of CVS Health Corp. Annual Report.

3 2024 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 63.22 × 1,260,795,063


The financial data demonstrates notable fluctuations in equity and enterprise value over the five-year period.

Common Equity (Market Value)
Common equity experienced a significant increase from 2020 to 2021, rising from $92,490 million to $137,538 million. However, starting in 2022, there was a reversal in this trend with a decline each subsequent year, reaching $79,707 million by 2024. This indicates a peak in market value of common equity in 2021, followed by a sustained downward trend.
Total Equity
Total equity closely mirrored the pattern of common equity, increasing sharply between 2020 and 2021 from $92,802 million to $137,844 million. Following this peak, total equity decreased over the next three years, falling to $79,877 million at the end of 2024. The similarity in movement suggests a consistent relationship between common equity and total equity levels.
Total Equity and Debt
The combined total of equity and debt rose substantially from $157,449 million in 2020 to $194,020 million in 2021, which marks the highest point during the period. Thereafter, a decline is observed each year, with the value decreasing to $146,147 million in 2024. This pattern indicates a period of deleveraging or reduction in combined capital after 2021.
Enterprise Value (EV)
The enterprise value followed a similar trajectory as total equity and debt, increasing from $146,595 million in 2020 to a peak of $181,495 million in 2021. From 2022 onward, enterprise value progressively decreased, ending at $135,154 million in 2024. This decline suggests a reduction in market capitalization or debt levels affecting the overall valuation of the company post-2021.

Overall, the data reveals a pronounced growth in equity and enterprise value metrics in the year 2021, followed by a consistent decline from 2022 through 2024. These trends may reflect broader market conditions, changes in company performance, capital structure adjustments, or investor sentiment shifts affecting valuation and capital balances during the latter years.